Affiliation:
1. Ministry of Health, Singapore
2. National Neuroscience Institute, Singapore
3. National University of Singapore, Singapore
Abstract
Introduction: The purpose of the present study was to evaluate the validity of the EQ-5D in patients with Parkinson’s disease (PD) in Singapore.
Materials and Methods: In a cross-sectional survey, patients with PD completed English or Chinese version of the EQ-5D, the 8-item Parkinson’s disease questionnaire (PDQ-8), and questions assessing socio-demographic and health characteristics. Clinical data were retrieved from patients’ medical records. The validity of the EQ-5D was assessed by testing a-priori hypotheses relating the EQ-5D to the PDQ-8 and clinical data.
Results: Two hundred and eight PD patients (English speaking: 135) participated in the study. Spearman correlation coefficients between the EQ-5D and PDQ-8 ranged from 0.25 to 0.75 for English-speaking patients and from 0.16 to 0.67 for Chinese-speaking patients. By and large, the EQ-5D scores were weakly or moderately correlated with Hoehn and Yahr stage (correlation coefficients: 0.05 to 0.43), Schwab and England Activities of Daily Living score (correlation coefficients: 0.10 to 0.60), and duration of PD (correlation coefficients: 0.16 to 0.43). The EQ-5D index scores for patients with dyskinesia or “wearing off” periods were significantly lower than those without these problems. The EQ-5D Visual Analog Scale (EQ-VAS) scores also differed for English-speaking patients with deferring dyskinesia, “wearing off” periods, or health transition status; however, such differences were not observed in patients who completed the survey in Chinese.
Conclusions: The EQ-5D questionnaire appears valid for measuring quality of life in patients with PD in Singapore. However, the validity of EQ-VAS in Chinese- speaking patients with PD should be further assessed.
Key words: EQ-5D, Health-related quality of life, Parkinson’s disease
Publisher
Academy of Medicine, Singapore
Reference24 articles.
1. Rabin R, de Charro F. EQ-5D: a measure of health status from the EuroQol Group. Ann Med 2001;33:337-43.
2. Gold MR, Patrick DL, Torrance GW, Fryback DG, Hadorn DC, Kamlet MS, et al. Identifying and valuing outcomes. In: Gold MR, Siegel JE, Russell LB, Weinstein MC,editors. Cost-effectiveness in Health and Medicine. New York, NY: Oxford University Press, 1996.
3. Drummond MF, Sculpher MJ, Torrance GW, O’Brien BJ, Stoddart GL. Cost-utility analysis. In: Methods for the Economic Evaluation of Health Care Programmes. 2nd ed. Oxford: Oxford University Press, 1997.
4. Reuther M, Spottke EA, Klotsche J, Riedel O, Peter H, Berger K, et al. Assessing health-related quality of life in patients with Parkinson’s disease in a prospective longitudinal study. Parkinsonism Relat Disord 2007;13:108-14.
5. Noyes K, Dick AW, Holloway RG; Parkinson Study Group. Pramipexole versus levodopa in patients with early Parkinson’s disease: effect on generic and disease-specific quality of life. Value Health 2006;9:28-38.
Cited by
4 articles.
订阅此论文施引文献
订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献